SEC Form 4 · accession 0001209191-18-026910
NovoCure Ltd · NVCR
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Michael J. Ambrogi
Officer — Chief Operating Officer
Period of report
Apr 26, 2018
Accepted (ET)
Apr 30, 2018 · 5:56 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001645113
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Ordinary SharesF1 | Apr 26, 2018 | M | 20,000 | $3.44 | A | 166,558 | D | |
| Ordinary SharesF1 | Apr 26, 2018 | S | 13,572 | $26.00 | D | 152,986 | D | |
| Ordinary SharesF1 | Apr 26, 2018 | S | 1,800 | $26.01 | D | 151,186 | D | |
| Ordinary SharesF1 | Apr 26, 2018 | S | 4,300 | $26.025 | D | 146,886 | D | |
| Ordinary SharesF1 | Apr 26, 2018 | S | 328 | $26.05 | D | 146,558 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Options to Buy Ordinary SharesF2 | $3.44 | Apr 26, 2018 | M | 20,000 | D | — | Dec 13, 2021 | Ordinary Shares | 20,000 | 28,695 | D |
Explanation of responses
- F1These shares were sold pursuant to a Rule 10b5-1 trading plan adopted by Mr. Ambrogi.
- F2Fully vested as of the date hereof.